Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.
Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.
Biodesix announced that the U.S. Patent & Trademark Office has issued four patents for the protection of the company's products and technology.
Biodesix has received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center.
Biodesix's Paul Beresford will present at the 2011 Biotech Showcase conference taking place January 10–12th at the Parc 55 Wyndham in San Francisco, CA
The intention of the biomarker analysis was to evaluate the ability of VeriStrat, to predict patient outcomes with a combination regimen.
Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors.
Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award, developing valuable products and services.
Biodesix announced today that the United States Patent and Trademark Office has awarded to the company patent number 7,736,905.
Phase III trial shows that VeriStrat identified patients likely to respond to erlotinib (Tarceva.)